Protein Transduction Domain-fused Disheveled Binding Motif (PTD-DBM) is a synthetic peptide that works in conjunction with CXXC5. This hair loss-linked endogenous protein acts as a negative feedback modulator of the Wnt/-catenin pathway.
PTD-DBM applied topically promotes the formation of new hair follicles and prevents hair loss. PTD-DBM and valproic acid work together to promote hair regrowth and wound-induced hair neogenesis.
The Mechanism of Action of PTD-DBM Peptide
CXXC5 acts as a reversible modulator on the Wnt/-catenin nerve tract, which is involved in wound healing and hair regrowth. It is known as the hair loss catalytic enzyme. CXXC5 forms a bond with the Dvl protein, which inhibits hair regeneration and follicle development. PTD-DBM prevents CXXC5 from binding to the disheveled protein. It works as a negative modulator of the entire process. When PTD-DBM prevents CXXC5 from becoming a disheveled protein, the Wnt/-catenin pathway is activated, inducing hair regrowth and wound-induced hair follicle neogenesis.
PTD-DBM inhibits the activities of body enzymes and hormones that shrink hair follicles, gradually restoring the strands at the stem cell level. PTD-DBM peptide prevents hair volume loss while stimulating the formation of new cavities for hair growth.
The Medical Benefits and Functions of PTD-DBM Peptide
The most typical cause of hair loss, androgenetic alopecia, is permanent hair loss from the scalp. When PTD-DBM peptide is applied topically alone or in combination with local valproic acid, the chemical pathway that causes hair shrinkage is inhibited. The application of the peptide for six to twelve weeks results in the growth of newer and healthier hair follicles. This action is significant because new hair growth is consistent over time.
The Impact of PTD-DBM Peptide on Androgenetic Alopecia
The first side effects of Androgenetic Alopecia are the regression of the frontal hairline and hair loss in the vertex or crown region of the head. It progresses and causes total hair loss on the frontal and vertex scalps.
The anagen phase, catagen phase, and telogen phase are the three stages of hair growth. The anagen phase is shortened due to androgen hypersecretion, specifically testosterone. It causes hair to thin and fall out suddenly, and the anagen phase lasts only a few months.
The most crucial cellular pathway that regulates hair growth in hair follicles is the Wnt/-catenin pathway. Wnt proteins are released, which bind to the LDL-related protein LRP, deactivating glycogen synthase kinase-3 (GSK-3). GSK-3 inhibits -catenin’s actions in the hair follicle.
According to Professor Kang-Yell Choi’s research, CXXC-type zinc finger protein 5 (CXXC5) is expressed aggressively in the scalps of Alopecia patients. CXXC5 inhibits the Wnt/-catenin signaling pathway. CXXC5 accomplishes this by binding to the Dvl protein, hindering the growth and health of both new and existing hair follicles.
By inhibiting the actions of CXXC5 and Dvl protein, PTD-DBM reduces the prevalence of androgenetic alopecia, resulting in increased hair follicle growth and the anagen phase of the hair growth cycle. PTD-DBM actions result in healthier and more robust hair and less hair loss; when the peptide is in symbiosis with valproic acid, its potency increases.
How PTD-DBM Peptide Enhances the rate of Wound Healing
The Wnt/-catenin signaling pathway is essential for wound healing and skin break fibrosis. The CXXC5 regulates it via a negative feedback mechanism. The CXXC5 binds to the Disheveled (Dvl) protein, inhibiting the Wnt/-catenin signaling pathway.
Inhibiting CXXC5 activities in mice promotes wound healing by stimulating collagen and keratin synthesis, specifically skin wound healing.
Furthermore, the PTD-DBM peptide inhibits the CXXC5-Dvl domain’s actions by preventing protein-to-protein interactions between CXXC5 and Dvl proteins. As a result, the Wnt/-catenin pathway becomes more active, inducing collagen and keratin synthesis and increased dermal fibrosis. Notably, the body can use wound healing processes as well.
The actions of PTD-DBM Peptide in combination with Valproic Acid
Valproic acid is used to treat seizures and mental/mood disorders (such as bipolar disorder’s manic phase) and to prevent migraine headaches. It works by rebalancing the natural substances in the brain (neurotransmitters).
The acid is critical to the potency of the PTD-DBM peptide. Valproic acid, combined with PTD-DBM, has been shown to accelerate the activation of the Wnt/-catenin signaling pathway. It increases the effectiveness of the following threefold:
- The activation of the Wnt/β-catenin pathway.
- The inhibition of the binding action of CXXC5 to the Disheveled protein.
- The generation of hair follicles.
Regardless of the medical benefits of the PTD-DBM peptide, it is a research peptide/chemical limited to educational and clinical purposes, not for human use or consumption.
Disclaimer: The products mentioned are not for human or animal consumption. All the information shared in this article is for educational purposes only.